RenovoRx (RNXT) Cost of Revenue (2025 - 2026)
RenovoRx (RNXT) posted Cost of Revenue of $84000.0 for Q1 2026, up 200.0% sequentially from $28000.0 in Q4 2025, and down 10.64% YoY from $94000.0 in Q1 2025.
RenovoRx (RNXT) Cost of Revenue (2025 - 2026) Analysis & Trends
RenovoRx has reported Cost of Revenue for 2 years, with the latest figure at $84000.0 in Q1 2026.
- Quarterly Cost of Revenue fell 10.64% year-over-year to $84000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $317000.0 (changed N/A YoY) and the FY2025 annual result came in at $327000.0, changed N/A from the prior year.
- Cost of Revenue advanced to $84000.0 in Q1 2026 per RNXT's latest filing, from $28000.0 in the prior quarter.
- Over five years, Cost of Revenue peaked at $152000.0 in Q2 2025 and troughed at $28000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 | 143,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 143,000.00 |
| Jun 30, 2026 | 143,000.00 |
| Mar 31, 2026 | 84,000.00 |
| Mar 31, 2026 | 84,000.00 |
| Dec 31, 2025 | 28,000.00 |
| Dec 31, 2025 | 28,000.00 |
| Sep 30, 2025 | 53,000.00 |
| Sep 30, 2025 | 53,000.00 |
| Jun 30, 2025 | 152,000.00 |
| Jun 30, 2025 | 152,000.00 |
| Mar 31, 2025 | 94,000.00 |
| Mar 31, 2025 | 94,000.00 |